This protocol applies to patients with castration-sensitive prostate cancer who have developed bone metastases — a distinct clinical subpopulation whose management differs meaningfully from castration-resistant disease stages.
The evidence base for bone metastases in castration-sensitive prostate cancer is specific to this disease state. Bone-protective agents that are used in other prostate cancer settings have not demonstrated benefit here and are not approved for this population. The appropriate approach is defined by the protocol for this precise clinical scenario.
DOI: 10.1007/s12094-016-1590-1
In contrast, zoledronic acid has not demonstrated any benefit in castration-sensitive prostate cancer.
Therefore, zoledronic acid is not approved for patients with bone metastases from castration-sensitive prostate cancer.
View source ↗